(CIDRAP) – Europe's drug regulatory agency today released its final review of a link between narcolepsy and the Pandemrix 2009 H1N1 vaccine, which recommends a labeling change that limits the vaccine's use in children and teens to when protection is needed and seasonal trivalent vaccine isn't available.
(CIDRAP News) Though pandemic flu activity continues to fall across much of the Northern Hemisphere, some parts of the world are hot spots for the virus, including parts of Europe, North Africa, and South Asia, the World Health Organization (WHO) reported today.
Norway OKs OTC antiviral salesTo ease response to the H1N1 pandemic, Norway is allowing over-the-counter sales of oseltamivir (Tamiflu) and zanamivir (Relenza), the Associated Press (AP) reported. The new policy starts tomorrow and is in effect until the middle of 2010. Norway has ordered 9.4 million doses of vaccine, but the manufacturer has reportedly not produced enough to meet demand.
(CIDRAP News) – A collection of new studies is demonstrating once again the ability of the pandemic H1N1 virus to make some people desperately sick and is raising questions about the potential strain on critical-care resources this fall and winter.
WHO's novel H1N1 flu case count tops 4,500The global number of people infected with the novel H1N1 influenza (swine flu) virus rose to 4,694 from 30 countries, the World Health Organization (WHO) reported today. The count includes 1,626 cases and 48 deaths in Mexico and the 2,532 cases and 3 deaths reported in the United States as of yesterday. Canada has reported 284 cases and one death. [WHO update 25]
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.